Short-term oral treatment of canine benign prostatic hypertrophy with chlormadinone acetate.
Ten beagle dogs (4-8 years of age) with benign prostatic hypertrophy were treated daily for 7 or 14 days by a daily oral administration of chlormadinone acetate (CMA), an anti-androgenic preparation, at a dose of 0.5 or 2.0 mg/kg/day. The groups of dogs treated with CMA at a dose of 2.0 mg/kg showed a greater reduction of the prostatic volume during 7 or 14 days of treatment than the group treated with 0.5 mg/kg of CMA. At 56 and 84 days after the start of CMA treatment, prostate volume was reduced to 63 and 79% of the pre-administration volume, respectively. No marked decrease in plasma LH or testosterone was found after the CMA treatment. These results indicate that the therapeutic effects of 7-day oral treatment with CMA at 2.0 mg/kg/day in dogs with BPH last for about three months or longer without side effects.
Orima
H
H
Department of Radiology, Nippon Veterinary and Animal Science University, Tokyo, Japan.
Shimizu
M
M
Tsutsui
T
T
Kawakami
E
E
Ogasa
A
A
D000284:Administration, Oral; D000818:Animals; D002715:Chlormadinone Acetate / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000662:veterinary*
D002715:Chlormadinone Acetate